(Q30886689)

27 June 2017

1 reference

title

Treatment optimization in multiple sclerosis: report of an international consensus meeting (English)

1 reference

27 June 2017

International Working Group for Treatment Optimization in MS

series ordinal

1

1 reference

27 June 2017

1 January 2004

1 reference

European Journal of Neurology

27 June 2017

1 reference

27 June 2017

11

1 reference

27 June 2017

1

1 reference

27 June 2017

43-47

1 reference

MRI in the diagnosis and management of multiple sclerosis

27 June 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00711.X

Quality of life during the first 6 months of interferon-beta treatment in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00711.X

The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00711.X

International consensus statement on the use of disease-modifying agents in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00711.X

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00711.X

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00711.X

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00711.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00711.X

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00711.X

Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00711.X

Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00711.X

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00711.X

10.1046/J.1351-5101.2003.00711.X

21 January 2018

Identifiers

DOI

1 reference

27 June 2017

1 reference

PubMed ID

14692887